



CYCLO G6™
Glaucoma Laser System

SAFE
Efficacious

MicroPulse® P3

GLAUCOMA DEVICE



Innovative Cyclophotocoagulation
with MicroPulse Technology
Powered by the New CYCLO G6™
Glaucoma Laser System

EFFICIENT
EASY
GLAUCOMA
SPECIFIC
NON-destructive
ESSENTIAL
REPEATABLE
NON-incisional
PREDICTABLE
ECONOMICAL





Excellent Safety Profile

The MicroPulse® P3 Glaucoma Device (MP3) powered by the CYCLO G6™ Glaucoma Laser System enables a versatile procedure with multiple safety benefits:


- Non-Incisional
- Minimal to no inflammation post-op
- Patient downtime is significantly low
- Repeatable
- Predictable

2014 Randomized study shows MicroPulse P3 has similar IOP reduction as G-Probe with higher success rate and no hypotony¹

	MicroPulse TSCPC	TSCPC
Pre-op IOP	36.5 mmHg	35.0 mmHg
N Total of 48	24 pts	24 pts
Average Follow-up	17.5 months	17.5 months
IOP Reduction	45%	45%
Success Rate (≤21 mmHg at 18 months)	75%	29%
Prolonged Hypotony	0	5
Mean # of Treatments	1.6	1.3



Pre Treatment.




Post Treatment with MP3. No detectable evidence of tissue damage.

Images courtesy of A/Professor Paul Chew, NUHS

Proprietary MicroPulse® Technology

MicroPulse technology finely controls thermal elevation by “chopping” a continuous-wave (CW) laser beam into a train of repetitive short pulses allowing tissue to cool between pulses and reduce thermal buildup preventing visible tissue damage.





“The MicroPulse P3 device has become an essential part of my armamentarium for use in glaucoma surgical procedures. It provides a very safe and efficacious solution for IOP control. I have used MicroPulse P3 for some of my most complicated cases but also I feel comfortable enough using it for patients with earlier disease in which we want to avoid a filtering bleb or the placement of hardware in the eye.”

Robert Noecker, MD, MBA




Glaucoma Therapy Device Options

MicroPulse® P3 and G-Probe™ devices are used to deliver laser energy for the treatment of glaucoma.



DEVICE COMPARISON	G-PROBE	MP3 PROBE
Glaucoma Treatment Stage	Refractory	Primary Open Angle
Repeatable Procedure	Yes	Yes
MicroPulse Technology	No	Yes
Destructive	Yes	No ^{1,2}
Therapy Location	Office & OR	Office & OR
CPT Code	66710	66710
SmartProbe Technology	Laser Parameter Memory Enabled	Laser Parameter Memory Enabled
Probe Tip Design	Wedge	Patented Curve



Patented Probe Tip Design, Patent No. 8,945,103

Efficacy - Confidence in IOP Control

Long-term results from National University Hospital (NUHS), Singapore prospective clinical study³:


- 33% IOP reduction at 18 months, N = 38 patients
- 61% med reduction (2.1 to 1.3)
- 73% success rate with 1.3 sessions

“The MicroPulse P3 device has given me over 30% IOP lowering. With patients that are non-compliant with their medication, or we are really trying to keep off their medication, the MicroPulse P3 device allows me to treat patients more aggressively.”




Steven Vold, MD

NUHS Prospective Clinical Study³



Multi-Center Retrospective Data^{2,4}



1. Aquino M, Barton K, Tan A, Sng C, Loon SC, Chew P. Micropulse versus continuous wave transcleral diode cyclophotocoagulation in refractory glaucoma: a randomized exploratory study. *Clin Experiment Ophthalmol.* 2015 Jan;43(1):40-6. doi 10.1111/ceo.12360 Epub 2014 Jun 21.

2. Radcliffe N, Vold S, Kammer J, Ahmed I, Parekh P, Noecker R, Khatana A. MicroPulse Trans-scleral Cyclophotocoagulation (mTSCPC) for the Treatment of Glaucoma Using the MicroPulse P3 Device. AGS, San Diego February 26 - March 1, 2015.

3. Tan A, Chockalingam M, Aquino M, Lim Z, See J, Chew P. Micropulse transcleral diode laser cyclophotocoagulation in the treatment of refractory glaucoma. *Clin Experiment Ophthalmol.* 2010;38(3):266-72

4. Jeffrey Kammer, MD, Vanderbilt Eye Institute, Nashville, TN | Anup Khatana, MD, Cincinnati Eye Institute, Cincinnati, OH | Robert Noecker, MD, MBA, Ophthalmic Consultants of Connecticut, Fairfield, CT | Parag Parekh, MD, MPA, Laurel Eye Clinic, Brookville, PA | Nathan Radcliffe, ND, Weill Cornell Medical College, New York, NY | Steven Vold, MD, Vold Vision, LLC, Fayetteville, AR



Specifications

Wavelength	810 nm infrared
Weight	3.9 kg (8.5 lb)
Dimensions	27 cm x 29.5 cm x 19.7 cm (10.6" W x 11.6" D x 7.8" H)
Connector Type	SmartProbe RFID with Laser Parameter Memory
Electrical	100-240 VAC, 50/60 Hz, <0.8 A
Cooling	Air cooled
Exposure Duration	CW-Pulse™: 10-9000 ms in 549 increments and continuous pulse up to 60 seconds
Exposure Interval	CW-Pulse: 10-3000 ms in 542 increments and One Pulse
MicroPulse® Duration	MicroPulse: 0.05-1.0 ms in 19 increments
MicroPulse Interval	MicroPulse: 1.0-10.0 ms in 90 increments
MicroPulse Duty Cycle	Continuously adjustable from 0.5%-50%, and preset selections of 5%, 10%, and 15% duty cycles
Aiming Beam	Diode laser, 635 nm nominal
Treatment Power	50-3000 mW, depending on delivery device

Additional Features

- Countdown Timer with audible/voice confirmations
- Programmable user presets for up to 10 individual presets
- Optional power-adjust wireless footswitch (wired footswitch included)
- Color LCD Touchscreen interface
- Backlit control knobs and Treat/Standby button
- Optional Remote Control (high viewing angle, color LCD touchscreen)

Ordering

Product	Product Number	Units per Box
MicroPulse P3	15522	6
G-Probe™	15980	6
Laser Console	CYCLO-G6-SYSTEM	-

CYCLO G6 supports single-use devices only.

Specifications are subject to change without notice. IRIDEX, the IRIDEX logo and MicroPulse are registered trademarks and CYCLO G6, G-Probe and CW-Pulse are trademarks of IRIDEX Corporation. All other trademarks are the property of their respective owners.

Products are covered by one or more of the following U.S. patents: 5,511,085; 5,982,789; 6,327,291; 6,540,391; 6,733,490; 7,766,904; 7,771,417; 7,909,816; 5,997,498; 6,073,759; 6,092,898; 6,217,594; 6,494,314; 6,585,679; 6,726,666; 6,800,076; 6,866,142; 7,537,593; 8,177,777; 8,945,103; 783783; 69530497.6; KR 348012; 0904615; 69706541.3; CA 2331837; AU 759193; JP 4149670; EP 1009684; CA 2286002; JP 449444; JP 4570696; JP 4819754; JP 5123973; JP 5133069. U.S. and international Patents Pending may apply.



Emergo Europe

Molenstraat 15, 2513 BH, The Hague, The Netherlands, Tel.: (31) (0) 70 345-8570, Fax: (31) (0) 70 346-7299

IRIDEX | 1212 Terra Bella Avenue | Mountain View, CA 94043 | 800.388.4747 (U.S. inquiries)
 info@iridex.com (U.S. & int'l inquiries) | www.iridex.com

